Evidence from the literature presented in this review is sufficient to conclude that variants in BARD1 can confer low–moderate risk to BC, especially TNBC, or modify risk to BC in carriers of pathogenic BRCA1 or BRCA2 variants (so-called double heterozygous carriers). Here, BARD1 is linked to breast cancer.